ELTROMBOPAG MSN 50mg tablets medication leaflet

B02BX05 eltrombopag • Blood and blood forming organs | Vitamin k and other hemostatics | Other systemic hemostatics

Eltrombopag is a medication used to treat thrombocytopenia, a condition characterized by a low platelet count in the blood. It is particularly indicated for patients with chronic idiopathic thrombocytopenic purpura or other conditions affecting platelet production.

This medication works by stimulating thrombopoietin receptors in the bone marrow, leading to increased platelet production. It is taken orally, usually once daily, as directed by a doctor.

Eltrombopag is generally well-tolerated but may cause side effects such as nausea, fatigue, headaches, or elevated liver enzymes. In rare cases, there may be an increased risk of blood clots.

It is important to strictly follow your doctor's recommendations and undergo regular blood tests to monitor the treatment's effects. Do not discontinue the medication without consulting a specialist.

General data about ELTROMBOPAG MSN 50mg

Substance: eltrombopag

Commercial code: W71183001

Concentration: 50mg

Pharmaceutical form: tablets

Product type: generic

Prescription restrictions: S - Medicines prescription reserved for use in certain specialized fields.

Marketing authorisation

Manufacturer: MSN LABS EUROPE LIMITED - MALTA

Holder: MSN LABS EUROPE LIMITED - MALTA

Number: 16054/2025/01

Shelf life: 2 years

Concentrations available for eltrombopag

12.5mg, 25mg, 50mg, 75mg